Specialty Pharmacy

Eli Lilly’s galcanezumab met its primary endpoint in a phase 3 study evaluating its use in the prevention of episodic cluster headaches.

Top news of the day from across the health care landscape.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.

The trial’s primary endpoint was a statistically significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

A new study questions medical marijuana’s role in reducing opioid use.

Top news of the day from across the health care landscape.

Officials with the FDA announced the approval subcutaneous formulation of tocilizumab (Actemra) for treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

Significant savings on biologic drugs from biosimilars may not be realized until litigation regarding patents is settled.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.

Top news of the day from across the health care landscape.

Population-based screening was found to be associated with a reduction in admissions, physician visits, and prescribed medication for individuals diagnosed with type 2 diabetes.

An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.

Fingolimod (Gilenya, Novartis) is the first FDA-approved treatment to treat multiple sclerosis in pediatric patients.

President Trump today called for "tougher negotiation, more competition, and much lower prices at the pharmacy counter," in a statement on lowering drug prices.

Top news of the day from across the health care landscape.

The recommendation means more men could be screened, now that the recommendation has been upgraded from its existing D recommendation to a grade C recommendation.

Top news of the week from Specialty Pharmacy Times.

Researchers found that women with advanced triple-negative breast cancer who had inherited a BRCA mutation benefited more from the chemotherapy carboplatin than standard treatment.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

A new study examines how chemoresistance evolves over time, which could lead to improved patient outcomes and survival.

According to the case study, an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.

Top news of the day from across the health care landscape.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses how data aggregators work with pharmacies and manufacturers to boost patient support services.

Text messages proactively gauge patients' struggle with opioid addiction to prevent relapse.

A dual immune-checkpoint blockade efficiently controlled the development of chronic lymphocytic leukemia by restoring functional antitumor immune response.

Luis Torres, MBA, vice president, Managed Care, BioPlus Specialty Pharmacy, discusses the importance of co-pay assistance programs for costly specialty drugs.

Top news of the day from across the health care landscape.

Rates of hospital inpatient admissions before and during use of ivacaftor found that overall and cystic fibrosis-related inpatient admissions fell by 55% and 81%, respectively.

The development and uptake of antiretroviral therapy for HIV has reduced the risk of certain cancers were previously prevalent.